Abstract:Abstract Background Globally rising rates of obesity and consequent metabolic diseases have been reflected in the inflammatory bowel disease (IBD) population. Non-alcohol fatty liver disease (NAFLD) is a common liver disorder associated with obesity, that occurs more frequently in people with IBD. Methods A prospective single-centre cohort study. In total, we recruited 203 patients from our IBD service in a tertiary academic hospital. 7 participants were excluded due to later diagnosed non-NAFLD liver disease. Following informed consent, participants underwent a fibroscan for liver stiffness (LSM) and controlled attenuation parameter (CAP) measurement, and blood tests for HbA1c and fasting lipids. Basic demographics, past medical history, exercise measured on the Godin-Shepard Leisure Time Physical Activity Questionnaire, physical functioning on SF-36 Questionnaire, blood pressure, CAP and LSM were recorded. T-test and Fishers exact test were used to test for statistical significance as appropriate. Results Of the 196 IBD patients included, 34.7% (n=68/196) had a healthy BMI, 34.7% (n=68/196) were overweight (BMI≥25-29.9), and 30.6% (n=60/196) were obese (BMI≥30). Overall, 16.3% (n=32) had a CAP score >294dB/m consistent with NAFLD, and 2.55% (n=5) had a LSM >8.1kPa consistent with fibrosis. When compared to those without NAFLD, those with NAFLD had higher BMIs, 26.9 vs 32.3 p<0.05. They also had a much higher incidence of diabetes 28.1% vs 0% p=0.0001, higher overall rates of abnormal HbA1C (≥6%), 21.9% (n=7/32) vs 6.4% (n=10/156) p=0.0121, and higher rates of abnormal HbA1c without a diagnosis of diabetes 13% (n=3/23) vs 6.45% (n=10/155) p=0.4043. Additionally, they had non-significant higher mean systolic blood pressure and higher rates of diagnosed hypertension. Compared to those without NAFLD, the NAFLD cohort had higher rates of diagnosed hypercholesterolaemia 34.4% (n=11/32) vs 15.3% (n25/163) p=0.022 and there were higher rates of elevated total cholesterol (>5mmol/L) in those not previously diagnosed with hypercholesterolaemia, 42.9% (n=9/21) vs 31.8% (n=47/148) p=0.3292. Participants with NAFLD also had lower exercise scores 17 vs 24.9 p=0.03543, and lower scores for physical functioning 71.9 vs 83.2 p=0.00676. Of particular note, they had more than double the 10-year risk of myocardial infarction or death determined by the Framingham risk scores for hard coronary heart disease, 2.48% vs 5.75%, p=0.00012. Conclusion Our study shows that people with concurrent NAFLD and IBD have a significant cardiovascular risk profile. With increased awareness of this, metabolic syndrome conditions should be screened for and treatment initiated where appropriate, to decrease cardiovascular related mortality in this cohort.

Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease (COPD) and metabolic fatty liver syndromes: a dangerous but neglected liaison

A Clinical Study of Pulmonary Function Changes in Patients with Nonalcoholic Fatty Liver Disease

Nonalcoholic fatty liver disease, nocturnal hypoxia, and endothelial function in patients with sleep apnea

Hypercoagulability in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): Causes and Consequences

Low Liver Density Is Linked to Cardiovascular Comorbidity in COPD: An ECLIPSE Cohort Analysis

Association of hepatic steatosis and liver fibrosis with chronic obstructive pulmonary disease among adults

Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases

Chronic Heart Failure in Patients with Nonalcoholic Fatty Liver Disease: Prevalence, Clinical Features, and Relevance

Prevalence and Prognostic Value of Non-Alcoholic Fatty Liver Disease in Patients Hospitalized With Decompensated Chronic Heart Failure

Association between non-alcoholic fatty liver disease and obstructive sleep apnea

Metabolic Disorders Combined with Noninvasive Tests to Screen Advanced Fibrosis in Nonalcoholic Fatty Liver Disease

P172 Metabolic disorders with non-alcoholic fatty liver disease in people with inflammatory bowel disease

Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease.

Impact of effective versus sham continuous positive airway pressure on liver injury in obstructive sleep apnoea: Data from randomized trials

Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese

Metabolic Dysfunction-associated Fatty Liver Disease is Associated with Greater Impairment of Lung Function Than Nonalcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease and heart failure with preserved ejection fraction: from pathophysiology to practical issues

Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis

Advanced Fibrosis Associates with Atherosclerosis in Subjects with Nonalcoholic Fatty Liver Disease.

Serum Interleukin‐8, Osteopontin, and Monocyte Chemoattractant Protein 1 Are Associated With Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease